The rise in the prevalence of cardiovascular disorders, adapting to new technological advances, new product launch, and strategic collaboration, rise in the patient pool are key factors contributing to the high CAGR of the Hypertrophic Cardiomyopathy Therapeutics market during the forecast period.
the global Hypertrophic Cardiomyopathy Therapeutics Market valued at USD 1.20 Billion in 2019 and is expected to reach USD 1.42 billion by the year 2027, at a CAGR of 2.1%. Hypertrophic cardiomyopathy (HCM) alters the functioning of the heart. Increasing prevalence of cardiovascular disorders, lifestyle habits like smoking and consumption of alcohol, obesity, and growth in the geriatric populations are the factors driving the growth of the market. However, the high-cost expenditure of treatment is restraining the market. According to the report, the World Health Organization (WHO) estimated that 17.9 million people died from cardiovascular diseases in the year 2016, which includes approximately 31% of all global deaths. According to the WHO, in 2016, more than 1.9 billion adults aged 18 years and older were overweight. Regionally, in Africa, the number of overweight children under five has increased by nearly 50% since 2000. Approximately half of the children under five who were overweight or obese in 2018 lived in Asia. The prevalence of obesity among children and adolescents aged 5-19 has risen dramatically. According to Canadian Community Health Survey, in 2018, nearly 63.1% of Canadian adults were either obese or overweight, in which approximately 26.8%, i.e., 7.3 million adults, were obese and another 9.9 million, i.e., 36.3% of Canadian adults were overweight. In 2019 approximately 35% of Americans were obese or overweight in the United States.
Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/2711
The report provides extensive coverage of the supply chain, key players of the industry, consumer base, company profiles, production and consumption rate, primary applications, and other relevant data. It provides an in-depth assessment of the key companies operating in the market along with their company profiles, business overview, production and manufacturing capacity, product portfolio, financial standing, global position, and business expansion plans. It also studies recent mergers and acquisitions, joint ventures, product launches, partnerships, collaborations, and agreements among other. The report also provides insights into new entrants and their strategic alliances to gain a robust footing in the market.
Key Manufacturers in the Global Hypertrophic Cardiomyopathy Therapeutics Market:
AstraZeneca, Merck, Pfizer, Sanofi, Gilead Sciences, Novartis, Teva Pharmaceutical, Correvio Pharma Industries, Abbot, Lupin
Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/2711
The report also provides an extensive regional segmentation to offer the readers key insights into the spread of the market over key geographical regions. It covers production and consumption patterns, import/export, supply and demand, consumer demand and behavior, key trends, and presence of key players in each region. The report also offer a country-wise analysis to impart a better understanding of the revenue growth of the market in each region.
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, France, Rest of Europe)
- Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)
- Latin America (Chile, Brazil, Argentina, Rest of Latin America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)
Drugs Outlook (Revenue in Million USD; (2017–2027)
- Antiarrhythmic Agents
- Beta-Adrenergic Blocking Agents
- Calcium Channel Blockers
Devices Outlook (Revenue in Million USD; (2017–2027)
- Other Medical Devices
End Use Outlook (Revenue in Million USD; (2017–2027)
To know more about the report @ https://www.reportsanddata.com/report-detail/hypertrophic-cardiomyopathy-therapeutics-market
Key Questions Addressed in the Report:
- What is the market size the global Hypertrophic Cardiomyopathy Therapeutics market is expected to reach over the forecast period? What is the expected CAGR?
- What are the key segments of the market?
- What are the key products and applications of the Hypertrophic Cardiomyopathy Therapeutics market?
- What factors are expected to drive and restrain market growth over the forecast period?
- What are the key outcomes of SWOT analysis and Porter’s Five Forces analysis?
Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/2711
Thank you for reading our report. The report can be customized based on regional segmentation and competitive landscape. Kindly get in touch with us to know more and our team will ensure the report is well suited to meet your requirements.
Browse more related reports:
Head of Business Development
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: [email protected]